FIELD: biochemistry.
SUBSTANCE: in particular, the invention relates to an antibody that specifically binds to human alpha-synuclein. Nucleic acid encoding the said antibody; a host cell for producing the said antibody; a pharmaceutical composition containing the said antibody are also disclosed. Disclosed are methods of treatment using the indicated antibodies; Lewy body detection and reducing Lewy body formation, using the specified antibodies; inhibiting the formation of synuclein aggregates with the help of the specified antibody; a method of producing the specified antibody and the specified cell.
EFFECT: invention makes it possible to effectively treat diseases associated with human alpha-synuclein.
38 cl, 4 ex, 4 tbl, 6 dwg
Title | Year | Author | Number |
---|---|---|---|
AGENTS, APPLICATION WAYS AND METHODS FOR TREATING SYNUCLEOPATHY | 2016 |
|
RU2765303C2 |
MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
ANTIBODIES AGAINST TRANSFERRIN RECEPTOR HAVING INDIVIDUALIZED AFFINITY | 2016 |
|
RU2729416C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
ANTIBODIES AGAINST ALPHA SYNUCLEIN | 2018 |
|
RU2787039C2 |
ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
Authors
Dates
2021-02-25—Published
2012-10-26—Filed